Short answer
Aardvark Therapeutics, Inc. (AARD) filed an 8-K current report with the SEC on October 23, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Exploratory efficacy data released from terminated Phase 3 HERO and OLE trials.
Aardvark Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Exploratory efficacy data released from terminated Phase 3 HERO and OLE trials
- Investor webinar held October 23, 2026 at 8:00 a.m. ET
- Results and presentation available in Exhibits 99.1 and 99.2, requiring review for efficacy details
- Terminated Phase 3 program limits immediate clinical and commercial relevance
Item EX-99.1 · Exhibit EX-99.1
- HERO trial stopped early with 67 of 90 planned participants, making all efficacy results exploratory
- OLE participants switching from placebo to ARD-101 showed average HQ-CT reduction of 6 points by Day 28
- ARD-101 generally well tolerated, but one cardiac serious adverse event involved 800 mg BID and pitolisant interaction
- FDA lifted ARD-101’s full clinical hold, enabling plans for a lower-dose Phase 3 program
- Company expects to resume PWS clinical activities in 2027, pending FDA alignment on trial design
Item EX-99.2 · Exhibit EX-99.2
- FDA clinical hold lifted in October 2026, allowing Aardvark to resume ARD-101 development for Prader-Willi syndrome
- HERO enrollment truncated at 67 participants versus planned 90, making efficacy results exploratory rather than confirmatory
- ARD-101 showed modestly greater hyperphagia improvement through Week 8, with benefits reversing after treatment stopped
- Safety generally favorable, but one Grade 4 polymorphic ventricular tachycardia event occurred at 800 mg BID with pitolisant
- Therapeutic-dose ECG studies found no QRS prolongation at 200 mg BID (n=45) or 400 mg BID (n=42)
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aardvark Therapeutics, Inc. 8-K filings
Get the next AARD 8-K as it lands
Follow AARD for push alerts, or ask the research agent what this filing means.